Top ▲
target has curated data in GtoImmuPdb
Target id: 2786
Nomenclature: CD22
Abbreviated Name: SIGLEC2
Family: Other immune checkpoint proteins, CD molecules, SIGLECs (conserved)
Gene and Protein Information  |
||||||
| Species | TM | AA | Chromosomal Location | Gene Symbol | Gene Name | Reference |
| Human | 1 | 847 | 19q13.12 | CD22 | CD22 molecule | |
| Previous and Unofficial Names |
| B-lymphocyte cell adhesion molecule | sialic acid binding Ig-like lectin 2 | SIGLEC-2 |
| Database Links |
|
| Alphafold | P20273 (Hs) |
| CATH/Gene3D | 2.60.40.10 |
| ChEMBL Target | CHEMBL3218 (Hs) |
| Ensembl Gene | ENSG00000012124 (Hs) |
| Entrez Gene | 933 (Hs) |
| Human Protein Atlas | ENSG00000012124 (Hs) |
| KEGG Gene | hsa:933 (Hs) |
| OMIM | 107266 (Hs) |
| Pharos | P20273 (Hs) |
| RefSeq Nucleotide | NM_001771 (Hs) |
| RefSeq Protein | NP_001762 |
| UniProtKB | P20273 (Hs) |
| Wikipedia | CD22 (Hs) |
Download all structure-activity data for this target as a CSV file 
| Antibodies | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Key to terms and symbols | Click column headers to sort | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Antibody Comments | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Triphase Accelerator and Catalent Biologics are collaborating on the development of TRPH-222 (CAT-02-106) which is an anti-CD22 ADC whose cytotoxic maytansinoid payload is attached using the protease-resistant SMARTag® linker technology [3]. This technology allows a higher drug-to-antibody ratio and enhances the therapeutic index. TRPH-222 has advanced to clinical evaluation for relapsed and/or refractory B-cell NHL (NCT03682796). | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Immunopharmacology Comments |
| CD22 (SIGLEC2) is a B cell I-type (Ig-type) lectin that binds glycans containing sialic acids. It is involved in adhesion and activation, mediates B cell-B cell interactions and may be involved in the localisation of B cells in lymphoid tissues. Most SIGLECs inhibit immune cell activation, via immunoreceptor tyrosine-based inhibitory (ITIM) motifs in their cytosolic domains. Hence, blockade of SIGLEC interactions restores immune cell activation, which is of interest for the treatment of B cell malignancies. CD22 is the target of the approved monoclonal antibody-drug conjugate (ADC) inotuzumab ozogamicin (FDA approved for ALL in 2017) and investigational ADC moxetumomab pasudotox. |
| Cell Type Associations | ||||
|
| Immuno Process Associations | ||
|
||
|
||
|
||
|
1. Beers R, Kreitman RJ, Pastan IH, Salvatore G. (2003) Mutated anti-cd22 antibodies with increased affinity to cd22-expressing leukemia cells. Patent number: WO2003027135. Assignee: Beers R, Kreitman RJ, Pastan IH, Salvatore G, US Gov Health & Human Serv. Priority date: 26/09/2001. Publication date: 03/04/2003.
2. DiJoseph JF, Armellino DC, Boghaert ER, Khandke K, Dougher MM, Sridharan L, Kunz A, Hamann PR, Gorovits B, Udata C et al.. (2004) Antibody-targeted chemotherapy with CMC-544: a CD22-targeted immunoconjugate of calicheamicin for the treatment of B-lymphoid malignancies. Blood, 103 (5): 1807-14. [PMID:14615373]
3. Drake PM, Carlson A, McFarland JM, Bañas S, Barfield RM, Zmolek W, Kim YC, Huang BCB, Kudirka R, Rabuka D. (2018) CAT-02-106, a Site-Specifically Conjugated Anti-CD22 Antibody Bearing an MDR1-Resistant Maytansine Payload Yields Excellent Efficacy and Safety in Preclinical Models. Mol Cancer Ther, 17 (1): 161-168. [PMID:29142069]
4. Kreitman RJ, Pastan I. (2011) Antibody fusion proteins: anti-CD22 recombinant immunotoxin moxetumomab pasudotox. Clin Cancer Res, 17 (20): 6398-405. [PMID:22003067]
5. Kreitman RJ, Tallman MS, Robak T, Coutre S, Wilson WH, Stetler-Stevenson M, Fitzgerald DJ, Lechleider R, Pastan I. (2012) Phase I trial of anti-CD22 recombinant immunotoxin moxetumomab pasudotox (CAT-8015 or HA22) in patients with hairy cell leukemia. J Clin Oncol, 30 (15): 1822-8. [PMID:22355053]
Other immune checkpoint proteins: CD22. Last modified on 15/01/2024. Accessed on 06/10/2024. IUPHAR/BPS Guide to PHARMACOLOGY, https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2786.
